ARGX vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ARGX dominates in value with a market cap of 35.72 billion USD, eclipsing TEVA’s 18.83 billion USD by roughly 1.90×.
TEVA carries a higher beta at 0.63, indicating it’s more sensitive to market moves, while ARGX remains steadier at 0.17.
ARGX and TEVA are both ADRs—easy access for U.S. investors to foreign shares without dealing with overseas exchanges.
| Symbol | ARGX | TEVA |
|---|---|---|
| Company Name | argenx SE | Teva Pharmaceutical Industries Limited |
| Country | NL | IL |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. Richard D. Francis |
| Price | 584.95 USD | 16.43 USD |
| Market Cap | 35.72 billion USD | 18.83 billion USD |
| Beta | 0.17 | 0.63 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | February 16, 1982 |
| ADR | Yes | Yes |
Performance Comparison
This chart compares the performance of ARGX and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- TEVA shows a negative P/E of -14.61, highlighting a year of losses, whereas ARGX at 51.17 trades on solid profitability.
- TEVA shows a negative forward PEG of -1.13, signaling expected earnings contraction, while ARGX at 1.36 maintains analysts’ projections for stable or improved profits.
- ARGX has a negative Price-to-Free Cash Flow ratio of -456.82, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, TEVA (P/FCF 24.72) indicates positive free cash flow generation.
| Symbol | ARGX | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.17 | -14.61 |
| Forward PEG Ratio (TTM) | 1.36 | -1.13 |
| Price-to-Sales Ratio (P/S, TTM) | 16.53 | 1.14 |
| Price-to-Book Ratio (P/B, TTM) | 7.76 | 3.00 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -456.82 | 24.72 |
| EV-to-EBITDA (TTM) | 4581.69 | 23.00 |
| EV-to-Sales (TTM) | 15.87 | 2.06 |
| EV-to-Free Cash Flow (TTM) | -438.66 | 44.65 |
Dividend Comparison
Neither ARGX nor TEVA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ARGX | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- TEVA posts a quick ratio of 0.74, indicating limited coverage of short-term debts from its most liquid assets—while ARGX at 6.68 enjoys stronger liquidity resilience.
- ARGX posts a negative interest coverage ratio (-20.85), reflecting an operating loss. TEVA, with its ratio at 0.44, also faces difficulty, as its operating earnings do not cover its interest expenses.
| Symbol | ARGX | TEVA |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 1.03 |
| Quick Ratio (TTM) | 6.68 | 0.74 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 2.71 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.44 |
| Interest Coverage Ratio (TTM) | -20.85 | 0.44 |